ArticleFrontiers in pharmacology2018
A Metabolomics Study on the Bone Protective Effects of a Lignan-Rich Fraction From Sambucus Williamsii Ramulus in Aged Rats.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management.Frontiers in pharmacology · 2026Review
- The impact of dyslipidemia on skeletal health - from an immunoregulatory perspective.Frontiers in immunology · 2026Review
- Osteoprotective Activity ofAntioxidants (Basel, Switzerland) · 2025Article
- Advances in omics technologies for traditional Chinese medicine in the prevention and treatment of metabolic bone diseases.Frontiers in pharmacology · 2025Review
- Lignans from Sambucus williamsii Protect Bone Via Microbiome.Current osteoporosis reports · 2024Review
- Identifying Herbal Candidates and Active Ingredients Against Postmenopausal Osteoporosis Using Biased Random Walk on a Multiscale Network.International journal of molecular sciences · 2024Article
- Identification of the Microbial Transformation Products of Secoisolariciresinol Using an Untargeted Metabolomics Approach and Evaluation of the Osteogenic Activities of the Metabolites.Molecules (Basel, Switzerland) · 2023Article
- Exploring the mechanism of traditional Chinese medicine in regulating gut-derived 5-HT for osteoporosis treatment.Frontiers in endocrinology · 2023Review
- The Lignan-Rich Fraction fromNutrients · 2022Article
- Serum metabolomic signatures of gestational diabetes in South Asian and white European women.BMJ open diabetes research & care · 2022Article
- Application of metabolomics in osteoporosis research.Frontiers in endocrinology · 2022Review
- Metabolomics in Bone Research.Metabolites · 2021Review
- Metabolic Alterations in Older Women With Low Bone Mineral Density Supplemented WithJBMR plus · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lignan-rich fraction (SWR) of Sambucus Williamsii Ramulus, a folk herbal medicine in China for treatment of bone diseases, has previously reported to exert protective effects on bone without exerting uterotrophic effects in ovariectomized (OVX) mice. The aim of the present study was to identify the potential metabolites and the associated metabolic pathways that contribute to the beneficial effects of SWR on bone
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.